AQST
Another day, another lawsuit
Aquestive Therapeutics is back in the legal hot seat. Faruqi & Faruqi says it’s investigating claims against the company and reminding investors that May 4 is the deadline to ask to be lead plaintiff in a federal securities class action already filed against AQST.
What sparked the case?
The lawsuit appears to center on an update from January 9, 2026, when Aquestive’s CEO said the FDA had flagged deficiencies in the NDA for Anaphylm. In plain English: the drug’s regulatory path hit a wall, and the company didn’t get the kind of clarity investors love to hear before they start doing victory laps.
Why investors should care
This isn’t just legal theater. Securities lawsuits can keep a lid on sentiment, add distraction for management, and fuel extra volatility when the market is already side-eyeing regulatory risk. If you own AQST, this is one of those “small headline, potentially annoying aftermath” situations.
Big picture
The clock is ticking toward the lead-plaintiff deadline, and that means the story is shifting from “what happened?” to “who’s steering the lawsuit now?” For shareholders, the real issue is still the same: can Aquestive clean up the FDA mess and rebuild trust, or is this one of those biotech plots that keeps adding sequel after sequel?